TMCnet News
Cytori Provides Twelve Month Data Update on Scleradec-I TrialCytori Therapeutics, Inc. (NASDAQ: CYTX) announced today preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. B. Granel and Prof. G. Magalon from the Assistance Publique des Hôpitaux de Marseille. In the previously published six month follow-up data, Cytori's ECCS-50 therapeutic showed:
The manuscript describing these data in detail can be viewed at http://ard.bmj.com/content/early/2014/08/10/annrheumdis-2014-205681.long. A preliminary assessment for 12 month follow-up data has been reviewed by the Company which management believes reflects:
The investigators have prepared and submitted for publication a scientific manuscript based on final 12 month data. Once this manuscript has been accepted for publication and a publication date announced, Cytori will provide an update to investors. About Cytori Therapeutics, Inc. Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori's proprietary technologies and products. For more information: visit www.cytori.com.
|